← All Fulgent Genetics, INC filings

Fulgent Genetics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
FLGT
Fulgent Genetics, INC
10-K: Fulgent Genetics: 2025 Revenue Growth Amidst Rising Losses
Fulgent Genetics reported a 14% revenue increase to $322.7 million in 2025, alongside a 42% rise in net loss to $60.5 million, driven by strategic acquisitions and R&D investments.
NASDAQ
FLGT
Fulgent Genetics, INC
10-K: Fulgent Genetics Reports Fiscal Year 2024 Results, Focuses on Therapeutic Development and Core Diagnostics
Fulgent Genetics' 10-K filing reveals a year of strategic shifts, balancing diagnostic services with a growing emphasis on therapeutic development amidst evolving regulatory landscapes.
NASDAQ
FLGT
Fulgent Genetics, INC
10-K: Fulgent Genetics 2023 10-K Filing: Focus on Strategic Shift Amidst COVID-19 Decline
Fulgent Genetics' 2023 10-K filing highlights a strategic shift towards precision medicine and oncology, amidst a significant decline in COVID-19 testing revenue.